If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBrown Advisory Regulatory News (BASC)

Share Price Information for Brown Advisory (BASC)

Share Price is delayed by 15 minutes
Get Live Data
1,665.00    57.50 (3.58%)
Bid:
1,595.00
Ask:
1,640.00
Spread: 45.00 (2.821%)
Market Cap: £184.02m
BASC Live PriceLast checked at - London Stock Exchange

Intraday Brown Advisory Share Chart

Strategic Review

Today 07:00

RNS Number : 4018L
Brown Advisory US Smaller Cos. PLC
08 July 2026
 

8 July 2026

For immediate release

 

Brown Advisory US Smaller Companies PLC

 

Legal Entity Identifier (LEI): 549300HKKL9K1NY4TW55

 

Strategic Review

 

The Board announces that it is conducting a Strategic Review of the future of the Company.

 

The Board continues to have confidence in the Portfolio Manager's philosophy and process, and in their ability to deliver positive results over the long term, as demonstrated historically. The Board also remains very positive on the prospects for US smaller companies as an asset class, where valuations are particularly attractive. However, the Board also recognises that more recent performance, despite delivering strong returns in absolute terms over the last year, has lagged the Company's benchmark by a significant margin. 

 

In the past 18 months, the Board has taken a number of actions aimed at enhancing the attractiveness of the Company and delivering value for shareholders. These include the reduction in management fees, effective from 1 January 2025, with fees now based on the lower of market capitalisation and NAV. The Board also remains committed to the use of share buybacks with the aim of reducing discount volatility.

 

The Board is cognisant of the Company's three-yearly continuation vote, to be held at this year's Annual General Meeting, and has been actively engaging with shareholders to understand their views.

 

Feedback from shareholders has been broadly supportive of the Company's investment objective and policy, as well as the processes and resources of the Portfolio Manager. There is also significant support for the Company's existing discount control mechanisms, including the three-yearly continuation vote, the five-year performance-related tender offer scheduled for 2028, and the use of share buybacks. 

 

However, a number of shareholders have indicated a preference for a liquidity opportunity in the shorter term. 

 

Against this backdrop, the Board is considering a range of strategic options, including the provision of a significant cash exit opportunity for shareholders. In evaluating these options, the Board will also have regard to the scale of the Company following any such transaction. 

 

The Strategic Review remains ongoing and there can be no certainty to its outcome. The Board will provide a further update in due course, taking into account the timing of the continuation vote at this year's AGM.

 

As part of the Review, the Board will not actively consider the option of a transaction that would be subject to the Takeover Code, and do not believe such a transaction is a possible outcome of that Review. 

 

Enquiries:

Brown Advisory US Smaller Companies PLC

Via Lansons

Stephen White (Chairman)

 

Singer Capital Markets (Corporate Broker) 020 7496 3000

Mark Bloomfield / James Fischer (Investment Banking)

Alan Geeves / Sam Greatrex / William Gumpel (Sales)

 

Lansons

Ed Hooper 07783 387713

edh@lansons.com 

 

Important Information

This announcement contains information that is inside information for the purposes of the Market Abuse Regulation (EU) No 596/2014 as implemented in the UK. The person responsible for arranging for the release of this announcement on behalf of the Company is Stephen White, Chairman.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSDFAWEMSESW
Date   Source Headline
23rd Feb 202610:22 amRNSNet Asset Value(s)
23rd Feb 20267:00 amRNSHalf Yearly Results to 31 December 2025
20th Feb 202610:11 amRNSNet Asset Value(s)
19th Feb 202610:04 amRNSNet Asset Value(s)
18th Feb 20269:41 amRNSNet Asset Value(s)
17th Feb 20269:57 amRNSNet Asset Value(s)
16th Feb 202610:42 amRNSNet Asset Value(s)
13th Feb 202610:11 amRNSNet Asset Value(s)
13th Feb 20269:00 amRNSPortfolio Update
13th Feb 20267:00 amRNSDirector Declaration
12th Feb 202610:14 amRNSNet Asset Value(s)
11th Feb 202610:11 amRNSNet Asset Value(s)
10th Feb 202611:01 amRNSNet Asset Value(s)
9th Feb 202610:00 amRNSNet Asset Value(s)
6th Feb 202610:26 amRNSHolding(s) in Company
6th Feb 202610:08 amRNSNet Asset Value(s)
5th Feb 202610:38 amRNSNet Asset Value(s)
4th Feb 202610:45 amRNSNet Asset Value(s)
3rd Feb 202611:01 amRNSNet Asset Value(s)
2nd Feb 20269:59 amRNSNet Asset Value(s)
30th Jan 202610:49 amRNSNet Asset Value(s)
29th Jan 202610:16 amRNSNet Asset Value(s)
28th Jan 202610:08 amRNSNet Asset Value(s)
27th Jan 20269:47 amRNSNet Asset Value(s)
26th Jan 202610:07 amRNSNet Asset Value(s)
23rd Jan 202610:18 amRNSNet Asset Value(s)
22nd Jan 202610:01 amRNSNet Asset Value(s)
22nd Jan 20267:00 amRNS-RKepler Trust Intelligence: New Research
21st Jan 202610:37 amRNSNet Asset Value(s)
20th Jan 20269:56 amRNSNet Asset Value(s)
19th Jan 202610:38 amRNSNet Asset Value(s)
16th Jan 202610:30 amRNSNet Asset Value(s)
15th Jan 20269:49 amRNSNet Asset Value(s)
15th Jan 20269:00 amRNSPortfolio Update
14th Jan 202610:02 amRNSNet Asset Value(s)
13th Jan 20269:57 amRNSNet Asset Value(s)
12th Jan 202610:15 amRNSNet Asset Value(s)
9th Jan 202610:31 amRNSNet Asset Value(s)
8th Jan 202610:01 amRNSNet Asset Value(s)
7th Jan 202610:14 amRNSNet Asset Value(s)
6th Jan 202610:16 amRNSNet Asset Value(s)
5th Jan 202610:42 amRNSNet Asset Value(s)
2nd Jan 202612:04 pmRNSNet Asset Value(s)
2nd Jan 202610:00 amRNSTotal Voting Rights
31st Dec 202510:30 amRNSNet Asset Value(s)
30th Dec 202510:28 amRNSNet Asset Value(s)
29th Dec 202511:49 amRNSNet Asset Value(s)
29th Dec 202510:00 amRNSNet Asset Value(s)
24th Dec 202510:06 amRNSNet Asset Value(s)
23rd Dec 202510:15 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.